A phase I study of intrathecally administered recombinant human HGF (rhHGF) for ALS was conducted from 2011 to 2015 at Tohoku University, Japan [30], and a phase II study began in May 2016. The gene discussed is HGF; the disease is amyotrophic lateral sclerosis.